nach oben

Erschienen in:

01.08.2014 | Research Article

Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells

verfasst von: Jing Liu, Wenhao Shen, Yiting Tang, Jundong Zhou, Ming Li, Wei Zhu, Hongying Yang, Jinchang Wu, Shuyu Zhang, Jianping Cao

Erschienen in: Tumor Biology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

The current treatment for advanced nonsmall cell lung cancer (NSCLC) remains unsatisfactory due to resistance to chemotherapy and ionizing radiation. The ubiquitin-proteasome system (UPS) regulates multiple cellular processes that are crucial for the proliferation and survival of all kinds of cells. Carbobenzoxyl-leucinyl-leucinyl-leucinal-H (MG132), a specific and selective reversible inhibitor of the 26S proteasome, represents a novel approach for cancer therapy. However, whether MG132 can potentiate the effect of radiation against the growth and metastasis of NSCLC is not clear. We found that MG132 inhibited the proliferation of human NSCLC cell lines (A549 and H1299) in a dose- and time-dependent manner by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Then MG132 at a nontoxic dose (100 nM) was selected for following studies. Pretreatment of A549 and H1299 cells with 100 nM MG132 before ionizing radiation (IR) potentiated the anticancer effect of IR. Moreover, pretreatment with 100 nM MG132 before IR-enhanced radiation induced cell cycle arrest by decreased CyclinD1 but increased Wee1 expression in A549 and H1299 cells. In addition, pretreatment of MG132 combined with IR significantly suppressed cell migration and invasion abilities in NSCLC cell lines, which was accompanied by decreased expression of matrix metalloproteinase (MMP)-2 and MMP-9 in NSCLC cell lines. Taken together, our results demonstrate that MG132 enhances the antigrowth and antimetastatic effects of irradiation in NSCLC cells by modulating expression of cell cycle and invasion- related genes.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef

Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2013;39(3):252–60.PubMedCrossRef

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–74.PubMedCrossRef

de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011;29(8):1067–74.PubMedCrossRef

O'Rourke N, Roqué IFM, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;6, CD002140.PubMed

Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066–74.PubMedCrossRef

Sandler A. State-of-the-art treatment for advanced non-small-cell lung cancer. Oncology (Williston Park). 2003;17(12 Suppl 13):15–22.

Choi EK, Terai K, Ji IM, Kook YH, Park KH, Oh ET, et al. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia. 2007;9(8):634–42.PubMedCentralPubMedCrossRef

Jeong SY, Park SJ, Yoon SM, Jung J, Woo HN, Yi SL, et al. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization. J Control Release. 2009;139(3):239–45.PubMedCrossRef

10.

Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5(5):417–21.PubMedCrossRef

11.

Sorokin AV, Kim ER, Ovchinnikov LP. Proteasome system of protein degradation and processing. Biochemistry (Mosc). 2009;74(13):1411–42.CrossRef

12.

Goktas S, Baran Y, Ural AU, Yazici S, Aydur E, Basal S, et al. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology. 2010;75(4):793–8.PubMedCrossRef

13.

Wu WK, Cho CH, Lee CW, Wu K, Fan D, Yu J, et al. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 2010;293(1):15–22.PubMedCrossRef

14.

Yakovlev VA, Barani IJ, Rabender CS, Black SM, Leach JK, Graves PR, et al. Tyrosine nitration of IκBα: a novel mechanism for NF-κB activation. Biochemistry. 2007;46(42):11671–83.PubMedCentralPubMedCrossRef

15.

Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, Fan M, et al. NF-κB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res. 2009;171(1):9–21.PubMedCentralPubMedCrossRef

16.

Veuger SJ, Hunter JE, Durkacz BW. Ionizing radiation-induced NF-κB activation requires PARP-1 function to confer radioresistance. Oncogene. 2008;28(6):832–42.PubMedCentralPubMedCrossRef

17.

Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6(3):203–8.PubMedCrossRef

18.

Fukuyama R, Ng KP, Cicek M, Kelleher C, Niculaita R, Casey G, et al. Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Mol Carcinog. 2007;46(5):402–13.PubMedCrossRef

19.

Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5(9):2638–45.PubMed

20.

Han YH, Moon HJ, You BR, Park WH. The attenuation of MG132, a proteasome inhibitor, induced A549 lung cancer cell death by p38 inhibitor in ROS-independent manner. Oncol Res. 2010;18(7):315–22.PubMedCrossRef

21.

Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14(6):1649–57.PubMedCrossRef

22.

Escobar M, Velez M, Belalcazar A, Santos ES, Raez LE. The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol. 2011;2011:806506.PubMedCentralPubMedCrossRef

23.

Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005;63(5):1400–12.PubMedCrossRef

24.

Russo SM, Tepper JE, Baldwin Jr AS, Liu R, Adams J, Elliott P, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001;50(1):183–93.PubMedCrossRef

25.

Pajonk F, van Ophoven A, Weissenberger C, McBride WH. The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer. 2005;5:76.PubMedCentralPubMedCrossRef

26.

Warren G, Grimes K, Xu Y, Kudrimoti M, St Clair W. Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition. Oncol Rep. 2006;15(5):1287–91.PubMed

27.

Grimes KR, Daosukho C, Zhao Y, Meigooni A, St Clair W. Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection. Int J Oncol. 2005;27(4):1047–52.PubMed

28.

Bulk E, Yu J, Hascher A, Koschmieder S, Wiewrodt R, Krug U, et al. Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer. PLoS One. 2012;7(12):e44591.PubMedCentralPubMedCrossRef

29.

Zhang D, Chen C, Li Y, Fu X, Xie Y, Li Y, et al. Cx31. 1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis. J Cell Mol Med. 2012;16(5):1047–59.PubMedCrossRef

30.

Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67(3):257–74.PubMedCrossRef

31.

Liu YC, Chiang IT, Hsu FT, Hwang JJ. Using NF-κB as a molecular target for theranostics in radiation oncology research. Expert Rev Mol Diagn. 2012;12(2):139–46.PubMedCrossRef

32.

Li F, Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 2010;1805(2):167–80.PubMed

33.

Lin Y, Bai L, Chen W, Xu S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010;14(1):45–55.PubMedCentralPubMedCrossRef

34.

Pajonk F, McBride WH. Ionizing radiation affects 26 s proteasome function and associated molecular responses, even at low doses. Radiother Oncol. 2001;59(2):203–12.PubMedCrossRef

35.

Jung J, Kim EJ, Chung HK, Park HJ, Jeong SY, Choi EK. c-Myc downregulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer. Int J Oncol. 2012;40(2):385–90.PubMed

36.

Cervello M, Giannitrapani L, La Rosa M, Notarbartolo M, Labbozzetta M, Poma P, et al. Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med. 2004;13(5):741–8.PubMed

37.

Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000;60(21):5934–6.PubMed

38.

Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol. 2002;4(12):993–7.PubMedCrossRef

39.

Lavin MF, Birrell G, Chen P, Kozlov S, Scott S, Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat Res. 2005;569(1–2):123–32.PubMedCrossRef

40.

Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 1998;282(5395):1893–7.PubMedCrossRef

41.

Dancea HC, Shareef MM, Ahmed MM. Role of radiation-induced TGF-beta signaling in cancer therapy. Mol Cell Pharmacol. 2009;1(1):44–56.PubMedCentralPubMedCrossRef

42.

Luo J, Zhu W, Tang Y, Cao H, Zhou Y, Ji R, et al. Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo. Radiat Oncol. 2014;9:84. 25.PubMedCentralPubMedCrossRef

Titel: Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells
verfasst von: Jing Liu
Wenhao Shen
Yiting Tang
Jundong Zhou
Ming Li
Wei Zhu
Hongying Yang
Jinchang Wu
Shuyu Zhang
Jianping Cao
Publikationsdatum: 01.08.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 8/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2012-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Proteasome inhibitor MG132 enhances the antigrowth and antimetastasis effects of radiation in human nonsmall cell lung cancer cells

Abstract

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma

Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis

Generation of a monoclonal antibody specific to a new candidate tumor suppressor, cell adhesion molecule 2

Try113His and His139Arg polymorphisms in the microsomal epoxide hydrolase gene are not associated with risk of breast cancer

Prognostic value of CYP2W1 expression in patients with human hepatocellular carcinoma

Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Update Onkologie